SCHEMBL6100124

SCHEMBL6100124

CC(=O)CCC(=O)O[C@H]1C[C@H](n2ccc(NC(=O)c3ccccc3)nc2=O)O[C@@H]1CO

nearest known ligand 0.79

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.79
ABL1 P00519 1/20 0.57
RIN1 Q13671 1/20 0.57
RNASE1 P07998 1/20 0.46
P2RY6 Q15077 2/20 0.45
P2RY14 Q15391 2/20 0.45
NT5E P21589 2/20 0.45
SLC6A2 P23975 1/20 0.35
ADRB1 P08588 1/20 0.34
DNMT1 P26358 1/20 0.34
ROCK2 O75116 1/20 0.34
P2RY12 Q9H244 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16289468 1.00 POLB (0.79) POLBABL1RIN1RNASE1P2RY6
SCHEMBL17231094 0.93 POLB (0.69) POLBABL1RIN1RNASE1P2RY6
SCHEMBL5180666 0.92 POLB (0.67) POLBABL1RIN1RNASE1P2RY6
SCHEMBL10947631 0.91 POLB (0.66) POLBABL1RIN1RNASE1P2RY6
SCHEMBL23211670 0.91 POLB (0.86) POLBABL1RIN1RNASE1P2RY6
SCHEMBL23211669 0.91 POLB (0.86) POLBABL1RIN1RNASE1P2RY6
SCHEMBL16257644 0.89 POLB (0.64) POLBABL1RIN1RNASE1P2RY6
SCHEMBL13213637 0.89 POLB (0.64) POLBABL1RIN1RNASE1P2RY6
SCHEMBL15146153 0.89 POLB (1.00) POLBABL1RIN1RNASE1P2RY6
SCHEMBL6206103 0.86 POLB (0.78) POLBABL1RIN1RNASE1P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415835-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-16 US disclosed
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-23 US disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 US disclosed
EP-3974563-A1 CYCLIC PEPTIDES Chugai Seiyaku Kabushiki Kaisha (JP) 2022-03-30 EP disclosed
EP-2813512-B1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI PHARMACEUTICAL CO LTD (JP) 2021-03-31 EP disclosed
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-03-04 US disclosed
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-10-27 US disclosed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 US disclosed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 US disclosed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 US disclosed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 US disclosed
EP-2813512-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD Chugai Seiyaku Kabushiki Kaisha (JP) 2014-12-17 EP disclosed
EP-2813512-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD Chugai Seiyaku Kabushiki Kaisha (JP) 2014-12-17 EP disclosed
WO-2013100132-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD 中外製薬株式会社 (JP) 2013-07-04 WO disclosed
US-7019127-B2 Solution phase synthesis of oligonucleotides AVECIA LIMITED (GB) 2006-03-28 US disclosed
US-20050240015-A1 Solution phase synthesis of oligonucleotides AVECIA LIMITED (GB) 2005-10-27 US disclosed
EP-1325927-A2 Synthesis of oligonucleotides Avecia Limited (GB) 2003-07-09 EP disclosed
US-20030083490-A1 Solution phase synthesis of oligonucleotides AVECIA LIMITED 2003-05-01 US disclosed
EP-1003758-B1 SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AVECIA LTD (GB) 2003-04-09 EP disclosed
US-6506894-B1 Phosphonation; oxidation in situ with sulfur transfer agent AVECIA LIMITED (GB) 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R POLB 4572/4885ABL1 3088/4885RIN1 4216/4885
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R POLB 4572/4885ABL1 3088/4885RIN1 4216/4885
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R POLB 4572/4885ABL1 3088/4885RIN1 4216/4885
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R POLB 4572/4885ABL1 3088/4885RIN1 4216/4885
US-20030083490-A1 Solution phase synthesis of oligonucleotides NUDT1, POLR2E, POLRMT POLB 17/4885ABL1 2045/4885RIN1 4428/4885
US-20050240015-A1 Solution phase synthesis of oligonucleotides NUDT1, POLR2E, POLRMT POLB 17/4885ABL1 2045/4885RIN1 4428/4885
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R POLB 4572/4885ABL1 3088/4885RIN1 4216/4885
US-12415835-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R POLB 4572/4885ABL1 3088/4885RIN1 4216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.